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Summary. We address estimation of intervention effects in experimental designs in which (a)
interventions are assigned at the cluster level; (b) clusters are selected to form pairs, matched
on observed characteristics; and (c) intervention is assigned to one cluster at random within
each pair. One goal of policy interest is to estimate the average outcome if all clusters in
all pairs are assigned control versus if all clusters in all pairs are assigned to intervention.
In such designs, inference that ignores individual level covariates can be imprecise because
cluster-level assignment can leave substantial imbalance in the covariate distribution between
experimental arms within each pair. However, most existing methods that adjust for covariates
have estimands that are not of policy interest. We propose a methodology that explicitly
balances the observed covariates among clusters in a pair, and retains the original estimand of
interest. We demonstrate our approach through the evaluation of the Guided Care program.
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1. Introduction
Experimental designs often have the following three features: interventions are assigned at
the cluster level; clusters are selected to form pairs, matched on observed covariates; and in-
terventions are assigned to one cluster at random within each pair. One goal of policy interest
is to estimate the average outcome if all clusters in all pairs are assigned control versus if all
clusters in all pairs are assigned to intervention. The effect of such a policy is easy to under-
stand, because its definition or estimation does not have to depend on models. Such designs
are useful when individual-level randomization is not feasible due to practical constraints, and
when cluster assignment also reflects how the assignment would scale in practice.
The Guided Care program is a recent example of such a study (Boult et al., 2013). The
study’s goal was to assess the effect of Guided Care versus a control condition on functional
health and other patient outcomes among clinical practices serving chronically ill older adults.
In Guided Care, a trained nurse works closely with patients and their physicians to provide
coordinated care. The control group does not have access to such a nurse. To assess the effect
of the Guided Care intervention, the study recruited 14 clinical practices and matched them
in 7 pairs using clinical practice and patient characteristics, and within each pair assigned
randomly one clinical practice to Guided Care and the other to control.
A problem with cluster-level assignment is that it can leave substantial imbalances in the
covariates within pairs. However, existing methods to estimate effects in such designs rarely use
covariates in order to adjust for these imbalances. As a consequence, such methods, including
nonparametric as well as hierarchical (meta-analysis) approaches, although useful in other
ways (Imai et al., 2009), can leave large uncertainty in the results. Methods that do use
covariates usually estimate effects conditionally on covariates and cluster-specific random effects
(Thompson et al., 1997; Feng et al., 2001; Hill and Scott, 2009). With such methods, the
estimands are no longer of policy interest and lack meaning when the modelling assumptions
2
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are misspecified.
We propose an approach that explicitly balances the observed covariates between clusters
in a pair and still estimates causal effects of policy interest. In Section 2, we formulate the
matched-pair cluster randomized design through potential outcomes. We then characterize in
Section 3 the existing approaches to causal effects estimation and their complications. In Sec-
tion 4, we propose a covariate-calibration approach and develop inferences with and without
the need for assumptions for a hierarchical second level. Throughout these sections, the argu-
ments are demonstrated through the evaluation of the recent Guided Care program. Section 5
concludes with discussion.
2. The goal and design using potential outcomes
Consider a design that operates in pairs p = 1, . . . , n of clusters. In each pair p, the design
recruits two clusters (e.g., clinical practices) indexed by i = 1, 2, matched on qualitative and
quantitative characteristics, such as percentage of patients with private insurance, and where
each clinical practice serves a community, say with a large number of Np,i patients. The design
then assigns to each clinic one of two treatments, namely control (t = 1) or intervention (t = 2).
If clinical practice i of pair p is assigned treatment t, then potential outcomes Yp,i,k(t) (Rubin,
1974, 1978) are to be measured on a random sample of k = 1, . . . , np,i patients from the Np,i
patients served in that clinical practice. We label Fp,i(y; t), µp,i(t), and σ
2
p,i(t) the distribution
(at value y), mean and variance of the potential outcome Yp,i,k(t) within clinical practice i of
pair p. The average outcomes in pair p are
µp(t) := µp,i=1(t)pip,i=1 + µp,i=2(t)pip,i=2, (1)
3
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where “ := ” means “define”, pip,i=1 is the fraction of patients served by clinic i = 1, i.e.
Np,i=1/(Np,i=1 +Np,i=2), and similarly for pip,i=2. One goal of policy interest is to estimate the
average outcome if all clinical practices in all pairs are assigned control versus if all clinical
practices in all pairs are assigned intervention. In terms of the model, the goal is to estimate
a contrast between
µ(1) :=E{µp(t = 1)} and µ(2) := E{µp(t = 2)},
(2)
for example δeffect := µ(1)− µ(2),
which is the average outcome if all clusters had been assigned treatment 1 versus if all clusters
had been assigned treatment 2. Here, the expectations are taken over a larger population P of
pairs from which p = 1, . . . , n can be considered a random sample. Alternative estimands (e.g.
conditionally on the sample of pairs, Imai et al. (2009)) can be considered, although this does
not change the main issues discussed here.
Within each pair, the design assigns at random the intervention to one clinical practice and
the control to the other, independently across pairs. Because in this design the original ordering
i is arbitrary, and in order to ease comparisons with the existing meta-analytic approach (e.g.
Thompson et al. (1997)), for each pair p we relabel by c = 1 the clinical practice that is assigned
control, and by c = 2 the clinical practice that is assigned intervention. The quantities Yp,c,k(t),
Fp,c(y; t), µp,c(t) and σ
2
p,c(t) are then redefined based on this relabeling and the above definitions.
Then, the paired cluster randomized design implies the following:
Condition 1. The potential outcomes under treatments 1 and 2 in clinical practice c, and
the number of patients served by clinical practice c are exchangeable (in distribution over pairs)
between clinical practices c = 1 and c = 2, i.e.,
4
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pr
 
(Fp,c(·; 1), Fp,c(·; 2), Np,c)c=1 , (Fp,c(·; 1), Fp,c(·; 2), Np,c)c=2
 
pr
 
(Fp,c(·; 1), Fp,c(·; 2), Np,c)c=2 , (Fp,c(·; 1), Fp,c(·; 2), Np,c)c=1
 
=
where the arrows connect equal entries in arguments, and distribution pr is over pairs p in the
larger population P of pairs.
Condition 1 implies, for example, that the joint distribution of the “means and variances
under exposure to intervention” is the same for the clinical practices that are actually assigned
the intervention (clinical practices “2”) as it is for the clinical practices that are actually
assigned the control (clinical practices “1”). Figure 1 illustrates the structure of pairs, clinical
practices, and assigned treatments in this paired cluster randomized design, along with means
and variances of potential outcome distributions.
[Figure 1 here.]
Here we connect the observed data and existing methods to the above framework of potential
outcomes, because this helps understand the meaning of the assumptions, explicit or implicit,
required by the existing methods.
In order to estimate an effect such as δeffect of (2), consider first a particular pair p: we can
directly estimate the average potential outcome under control for the clinical practice assigned
to the control, namely µp,c=1(t = 1); and the average potential outcome under intervention
for the clinical practice assigned to the intervention, namely µp,c=2(t = 2). Specifically, for the
control clinical practice (c = 1) of pair p, let µˆp,c=1(t = 1) :=
1
np,c=1
∑np,c=1
k=1 Yp,c=1,k(t = 1) denote
the average of the observed outcomes, i.e., the potential outcomes under t = 1; and for the
intervention clinical practice (c = 2) of pair p, let µˆp,c=2(t = 2) :=
1
np,c=2
∑np,c=2
k=1 Yp,c=2,k(t = 2)
denote the average of the observed outcomes, i.e., the potential outcomes under t = 2. Then,
letting δˆcrudep = µˆp,1(1) − µˆp,2(2), and conditionally on pairs p whose clinical practices have
5
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particular values of (δcrudep , v
crude
p ), we have that
pr(δˆcrudep | δcrudep , vcrudep ) =˙Normal(δcrudep , vcrudep ), where
(3)
δcrudep := µp,1(1)− µp,2(2) and vcrudep =
σ2p,1(1)
np,1
+
σ2p,1(2)
np,2
.
Here, “=˙” means “approximately”, the notation pr(Ap | Bp) and E(Ap | Bp) means the distri-
bution and expectation, respectively, of characteristic Ap among pairs in the larger population
P that have characteristic Bp (if Bp is empty, the distribution and expectation are over all
pairs).
Remark 1. In a pair, the directly estimable (crude) contrast δcrudep is not a causal effect because
it compares different clinical practices under different treatments (Thompson et al., 1997).
However, the average, E(δcrudep ), over pairs is a causal effect, because the exchangeability of
potential outcomes and between clinical practices 1 and 2 (Condition 1 above) implies (proof
omitted) that
E(δcrudep ) = E{µp(t = 1)} − E{µp(t = 2)}, which is δeffect , (4)
Thus, one can use the estimated differences, δˆcrudep , within each pair as in (3), and expression
(4), to estimate δeffect , either with no additional assumptions (i.e., by simply averaging δˆcrudep
over pairs), or under a hierarchical second level model.
Remark 2. The objective meaning that the potential outcomes assign to the terms in the
model (3) implies the following, subtle fact: if the pair-specific δcrudep are to be eliminated
(i.e., marginalized over) from the distribution (3), then δcrudep should be first integrated out of
6
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(3) based on the conditional distribution pr(δcrudep | vcrudep ), i.e.,
pr(δˆcrudep | vcrudep ) =
∫
pr(δˆcrudep | δcrudep , vcrudep ) · pr(δcrudep | vcrudep ) · d(δcrudep ). (5)
This becomes relevant when examining the existing hierarchical modeling methods.
We next discuss complications of existing methods for estimating the effect of intervention
δeffect . We demonstrate the arguments by assessing the effect of the Guided Care intervention
on the functional health outcome of the patients as measured by the physical component
summary of the Short Form (SF)-36 version 2 (Ware and Kosinski, 2001).
3. Complications with existing methods
3.1 Consequences when ignoring covariates.
Table 1 displays the observed average SF-36 scores for each of the seven pairs of practices
in the Guided Care study (see outcome rows denoted as uncalibrated). Also displayed are the
within pair differences in average SF-36 outcomes between control and intervention.
[Table 1 here ]
Using these outcome data and ignoring covariates, we first obtain the estimate of the overall
effect δeffect based only on the design-derived fact (4) that the average of δcrudep equals the
effect of interest δeffect (see Table 2, 1st level, “uncalibrated on covariates”). Because this first-
level approach makes no further assumptions about the joint distribution of pr(δcrudep , v
crude
p ),
the MLE of δeffect is simply the unweighted sample average of δˆcrudep , with its standard error
estimated by the jackknife. Table 2 also reports the permutation test of no true effect for any
person, by randomly permuting the labels of treatment within each pair.
For a hierarchical second-level (meta-analytic) inference, the current approach for paired-
clustered designs (e.g., Thompson et al., 1997; Feng et al., 2001; Hill and Scott, 2009) is based
7
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on integrating the likelihood in (3) over the marginal distribution pr(δcrudep ), to obtain:
pr∗(δˆcrudep | vcrudep , δeffect ) =
∫
pr(δˆcrudep | δcrudep , vcrudep ) · pr(δcrudep ) · d(δcrudep ); (6)
where pr(δcrudep ) = Normal(δ
effect , v2).
Table 2 (see 1st+2nd level, “uncalibrated on covariates”) shows inference for the effect
δeffect using the above likelihood (6), namely, the method of Thompson et al. (1997) with and
without profiling out the variance v2 (see row 3 and 4); and also inference based on the mean
of the posterior distribution of δeffect using the uniform shrinkage prior on v2 as suggested by
Daniels (1999) (see row 5). For comparison, we also obtained the two-sided tail probability
from the distribution of the MLE from (6) as obtained from all the permutation possibilities
of the intervention and control labels of clinical practices independently across pairs. None of
these results suggest any substantial effect for the intervention.
In general, the hierarchical and non-hierarchical methods without covariates can be inac-
curate for at least one of the following two reasons. First, any substantial covariate imbalances
between clinical practices within a pair can result in substantial uncertainty, which is reflected
in the variance of the estimators of the effect, and which may have influenced the point esti-
mate. For the Guided Care study, Table 3 shows that a number of covariates show substantial
imbalance between intervention and control groups. For example, the continuous covariate
Chronic Illness Burden has severe imbalances between the clinical practices in pairs 2, 5
and 7, with t-statistics being −3.07, −4.81 and 2.52, respectively.
[Tables 2, 3 here ]
The hierarchical model approach, in addition to its normality assumption, can be questioned
for the following subtle reason. In order to integrate out δcrudep from the likelihood (3) to obtain
a likelihood that, like (6), still depends on the variances vcrudep , one must integrate δ
crude
p with
8
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respect to the conditional distribution of the estimand δcrudep given the variance v
crude
p , as in
(5) of Remark 2, and not with respect to the marginal distribution pr(δcrudep ) as in (6). The
comparison of (6) to (5) shows that (6) implicitly assumes the following:
Condition 2. The estimand δcrudep and the variance v
crude
p of δˆ
crude
p at the first level are
independent across pairs p.
The motivation for using the likelihood (6) can be traced to Thompson et al. (1997, Section
5, Paragraph 2). There, inference for the paired-clustered design is assumed to have the same
random effects structure as that of DerSimonian and Laird (1986), who also assume Condition
2 but for a design that first randomly samples subjects from the population that a pair serves
and then completely randomizes them, regardless of their clinical practice. Call this simpler
design, a “paired-strata” design. We show below that violation of Condition 2 has more severe
implications for the paired-clustered than for the paired-strata design.
In the paired-strata design, the observed difference, say δˆ′p, in average outcomes between
intervention and control individuals within a pair has mean, say δ′p, equal to the causal effect
µp(2) − µp(1) of (2). This means that, if the intervention has no effect in any pair, i.e., the
null hypotheses, µp(1) = µp(2) for all p, is correct, then δ
′
p is a constant (0) and so Condition
2 is satisfied. As a result, an approach based on (6) is valid for testing µp(1) = µp(2) for all p
because Condition 2 is correct under the null hypothesis being tested in that design.
In the paired-clustered design, however, the mean, δcrudep , of δˆ
crude
p is not a causal effect
(see Remark 1 above) even if the intervention has no effect in any cluster, i.e., even if the null
hypotheses, µp,c(1) = µp,c(2) for all p and c, is correct. In particular, under this null, the mean
δcrudep is µp,1(1)−µp,2(1), i.e., the difference between clinical practices 1 and 2 if they had both
been assigned control. In practice, even after matching, the two clinical practices are expected
to have imbalances in characteristics of the patients or the doctors, so that δcrudep is expectedly
not zero, and, hence, Condition 2 can be violated. We then have the following result (proof in
9
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Appendix):
Result 1. If the intervention has no effect, µ(1) = µ(2), but Condition 2 is violated, then the
MLE of the causal effect δeffect based on (6) can converge to a non-zero value as the number
of sampled practices increases.
Therefore, it is important to try to assess the plausibility of Condition 2. For the Guided
Care study, Figure 3 (left) plots the estimated values of
√
vcrudep against δ
crude
p . Here there ap-
pear no noticeable warnings against independence. However, the covariate imbalances shown in
Table 3 could still be contributing to inaccurate estimates through large variances as discussed
earlier.
3.2 Complications with existing covariate methods.
Some existing proposals do incorporate covariates into the model for pr(δcrudep ) on the RHS
of likelihood (6). However, these approaches stop short of addressing the goal of estimating
effects of policy interest. In particular, such existing approaches (e.g., Thompson et al. (1997),
Sec.5.5, Feng et al. (2001)) define the treatment effect to be a contrast in the treatment coeffi-
cients of the posited model after conditioning on a particular value of the covariates and/or of
random effects specific to the clusters. The first problem with such a treatment effect is that,
its meaning is not objective: if, for example, the model is misspecified, then an effect set equal
to a contrast of coefficients in the model does not have a well defined physical interpretation.
The second problem is that, even if the model is correct, a treatment effect that is conditional
on the covariates and/or the clusters is not usually equal to the overall effect.
10
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4. Addressing the Problems
4.1 Calibration of observed covariate differences between clinical practices.
In order to use covariates to estimate the treatment effects in (2), we propose to first
construct calibrated pair-specific averages, for each treatment t = 1, 2, in the sense that the
distribution of the covariates reflected in the averages will be the same as the distribution
of covariates combined from both clinical practices of the pair. Inference for these calibrated
averages will then lead to inference for overall effects (2) with the gained precision of accounting
for the difference in observed covariates between the matched clinical practices.
This section uses notation for the following additional structure for pair p:
◦ Xp,c,k, for the measurement of a covariate vector before treatment administration, for the
kth sampled patient of clinical practice c;
◦ Gp,c(x), for the joint cumulative distribution function of the covariate vector Xp,c,k in
clinical practice c, evaluated at value x; and Gp(x) for the joint cumulative distribution
function (evaluated at x) of the covariate vector of a patient selected at random from
pair p (i.e., from the two clinical practices of that pair, combined);
◦ Fp,c(y | x; t), for the cumulative distribution function of the potential outcome Yp,c,k(t) in
clinical practice c, evaluated at value y among covariate levels x, if clinical practice c is
assigned treatment t; and let µp,c(x; t), for the mean of the latter distribution.
For pair p, consider now the estimable quantity, labelled as µcalibrp (t = 1), that is con-
structed by, first, stratifying the average outcome into the covariate levels of the clinical prac-
tice c = 1 (assigned to treatment 1), namely µp,c=1(x; t = 1), and then re-calibrating it with
respect to the covariate distribution of the two clinical practices combined (and similarly for
11
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t = 2):
µcalibrp,c=1 :=
∫
x
µp,c=1(x; t = 1)dGp(x), µ
calibr
p,c=2 :=
∫
x
µp,c=2(x; t = 2)dGp(x) (7)
To understand the above estimand, consider for example two clinical practices in a pair,
that, although matched as closely as possible with respect to, say, the percentage of patients
with a “low” or “high” risk covariate (x = low or high), the percentage of low risk in clinical
practices 1 and 2 is 75% and 85% respectively, i.e., still differs appreciably between the clin-
ical practices. Suppose also that clinical practice 2 serves twice as many patients as clinical
practice 1. Ignoring covariates, the quantity that can be directly estimated from the data for
representing the average outcome if both clinical practices are assigned treatment 1 is simply
the average outcome within clinical practice 1, µp,c=1(1), which can be expressed in terms of the
covariate as 0.75 ·µp,c=1(x = low; t = 1) + 0.25 ·µp,c=1(x = high; t = 1). When using covariates,
the calibrated average µcalibrp,c=1 is 0.82 · µp,c=1(x = low; t = 1) + 0.18 · µp,c=1(x = high; t = 1), be-
cause it generalizes the covariate-specific outcome averages under treatment 1 to the covariate
distribution for both clinical practices in which 0.751
3
+ 0.852
3
= 0.82 have low risk.
More generally, one should expect that the calibrated contrasts µcalibrp,c=1 − µcalibrp,c=2 , though
still not equal to the target causal effect µp(t = 1)− µp(t = 2) of (1) in each pair, should, (a)
share the property with the uncalibrated estimands, i.e., that they average over pairs to the
average causal effect δeffect of (4); and (b) provide a basis for more efficient estimators than
the uncalibrated contrasts. This is true if the design is more carefully formalized as follows:
Condition 3. The characteristics of a clinical practice, i.e., the distribution of potential
outcomes under treatments 1 and 2 conditionally on covariates, the distribution of covariates,
and the number of people served by clinical practice c, namely the vector of functions
[
Fp,c(· |
·, t = 1), Fp,c(· | ·, t = 2), Gp,c(·), Np,c
]
, is exchangeable (in distribution over pairs) between
12
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clinical practices c = 1 and c = 2.
Then we have the following:
Result 2. (a) Under Condition 3, the average over pairs of the covariate-calibrations, µcalibrp,c=1 ,
i.e., based on the clinical practice assigned to treatment 1 in each pair (see (7)) equals the aver-
age of the potential outcomes if the entire population had been assigned treatment 1 (similarly
for treatment 2); hence the estimable contrast
E{µcalibrp,c=1 } vs. E{µcalibrp,c=2 } (8)
equals the causal contrast (2); (b) if µp,c(x; t = c) are known, then the MLEs of E{µcalibrp,c=1 }
in (8) (and of the target estimands µ(t) in (2), due to (a) and the invariance property of the
MLE) are the averages, over the observed pairs, of the empirical analogues of (7):
∫
µp,c(x; t = c)dGˆp(x), c = 1, 2, (9)
where Gˆp is the weighted empirical distribution of covariates in pair p (the weight is determined
by Np,c).
Condition 3 implies Condition 1. The proof of Result 2 (a) follows by iterated expectations;
the proof of (b) follows because the empirical distribution Gˆp(x) as defined above is, under no
other assumptions, the MLE of Gp(x).
In practice, and simplifying the notation for the estimable averages µp,c(x; t = c) to µp,c(x),
one can consider modelling µp,c(x) for each (pair p, cluster c), with µp,c(x; θ), where
h{µp,c(x, θ)} = θp,c + θ′cov · x and h is a link function. (10)
13
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Since these models condition on the pairs and clusters, the parameter θ can be estimated by
weighted least squares estimator θˆ, based on the first moment residuals Yp,c,k − µp,c(Xp,c,k, θ),
where approximately
θˆ | θ,Σθˆ ∼ Normal(θ,Σθˆ), (11)
and where Σθˆ is the true variance-covariance matrix of θˆ, which can be estimated by the robust
variance-covariate matrix denoted by Σˆθˆ.
Based on these, the calibrated estimands in (7) can be estimated within each pair and
clinical practice, by
µ̂calibrp,c =
∫
µp,c(x, θˆ)dGˆp(x), for all p, c, (12)
whose joint distribution can be approximated by the delta method as
level 1 :

µ̂calibrp=1,c=1 µ̂
calibr
p=1,c=2
...
...
̂µcalibrp=N,c=1
̂µcalibrp=N,c=2
 | θ,Σµˆcalibr ∼ Normal


µcalibrp=1,c=1 µ
calibr
p=1,c=2
...
...
µcalibrp=N,c=1 µ
calibr
p=N,c=2
 ,Σµˆcalibr
 , (13)
and where Σµˆcalibr can be estimated by Σˆµˆcalibr .
4.2 Estimation of quantities of original interest
Expression (13) can be used for estimation of the causal contrast µ(1) vs. µ(2) (because of
Result 2(a)); here we focus on δeffect = µ(1) − µ(2). Specifically, setting δcalibrp = µcalibrp,c=1 −
µcalibrp,c=2 and δˆ
calibr
p = µ̂
calibr
p,c=1 − µ̂calibrp,c=2 we can consider the first or both levels of the following
14
Biometrics, doi: 10.1111/biom.12214
two-level model
level 1′ :

δˆcalibr1
...
δˆcalibrN
 |

δcalibr1
...
δcalibrN
 , θ,Σδˆcalibr ∼ Normal


δcalibr1
...
δcalibrN
 ,Σδˆcalibr
 , (14)
level 2′ : δcalibrp | δeffect , τ 2 ∼ Normal(δeffect , τ 2), p = 1, . . . , N, (15)
where expression (14) follows from (13), and the covariance matrix Σδˆcalibr , obtained by the delta
method, can be estimated by Σˆδˆcalibr .
Table 1 shows the results for the calibrated estimates as derived from expressions (13) and
(14) (see rows for outcome “calibrated on covariates”) for each of the seven pairs in the Guided
Care study. The covariates that are involved in the calibration are listed in Table 3. It is
notable that these calibrated differences, δˆcalibrp , are positive, in favor of the control condition,
for all pairs p.
Using these, Table 2 also reports the estimate of the overall effect δeffect , first based only
on the design-derived fact Result 2(a) that the average of δcalibrp equals the effect of interest
δeffect and on the estimation of each of δcalibrp by δˆ
calibr
p as in (14) (see 1st level, “calibrated on
covariates”). As with the uncalibrated first-level approach, this first-level calibrated approach
makes no further assumptions about the joint distribution of pr(δcalibrp ,Σδˆcalibr), and the MLE
of δeffect is the unweighted sample average of δˆcalibrp (here, its standard error is estimated by
the jackknife, although in general it is difficult to trust a normal approximation with seven
pairs). For this reason, we also calculated the significance level of the MLE by permutation of
the treatment labels, thus testing the hypothesis of no true effect in any person. In this case,
and because all calibrated estimated differences have the same sign, the permutation based
significance level is 2/(27) = 0.016 in favor of the control condition.
For a two-level approach based on (14) and (15), one can estimate δeffect , by first obtaining
15
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the marginalized likelihood, say, L(δeffect , τ 2,Σδˆcalibr). Then we estimated δ
effect by (i) the MLE
after Σˆδˆcalibr replaces Σδˆcalibr ; (ii) the MLE after profiling τ
2 out; and (iii) the posterior distribution
of δeffect using noninformative priors for τ 2 and δeffect . We use a uniform shrinkage prior for
the second-level variance τ 2 advocated by Daniels (1999). These results for the two-level
approach are given in Table 2 (see rows 1st+ 2nd level; MLE, pMLE, and Bayes, respectively).
As with the uncalibrated approach, the marginalized likelihood that uses (14) and (15)
assumes that δcalibrp is independent of Σδˆcalibr . Figure 3, right panel, plots estimates of the
square root of the diagonals of Σδˆcalibr ,
√
vcalibrp , versus estimates of δ
calibr
p . Although the
plot can be to some degree affected by measurement error, the R2 of 0.20 suggests that some
dependence exists. Although this dependence could be modeled in a modified second level, it is
unclear how convincing such an approach would be as it would introduce even more modeling
assumptions. To avoid this, we calculated instead the significance level of the two-level MLE
estimate when evaluated from the permutation distribution of the treatment labels.
4.3 Assessment of the hypothesis of no effect
The proposed approach, in addition to being robust for hypothesis testing when evaluated
by permutation, is likely to have a more general robustness property analogous to the one
arising in a simpler design. Specifically, in the design of complete randomization of units
(unpaired, unclustered), Rosenblum and van der Laan (2010) have shown that a certain class
of parametric models for covariates yield MLEs for the causal effect that are consistent for the
null value if indeed there is no effect on any person, even if the models are incorrect. Shinohara
et al. (2012) showed that an extended class of models has this robustness property if the models
satisfy an easy to check symmetry criterion.
For the matched-paired clustered-randomization design, analogous classes of models with
such robustness property may also exist. Specifically, suppose that, more generally than model
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(10), we conceptualize a parametric model as one that allows distributions mp,c(y | x) for the
outcome at value y given covariate at value x for each (pair,cluster) labelled (p, c). Many
flexible models mp,c(· | ·) (or, for brevity, mp,c), including (10), have the property that if, for
two pairs and their clusters
 p1c1 p1c2
p2c1 p2c2
 , the model allows the distributions
 m1,1 m1,2
m2,1 m2,2

then it also allows the distributions m2,2 m1,2
m1,2 m2,2
 and
 m1,1 m2,1
m2,1 m1,1
 .
The intuition of this property is that the model allows exchangeable distributions between
any two observed pairs. Following a similar reasoning to that of Shinohara et al. (2012), we
hypothesize that if (a) there is no effect of intervention in the distribution of any cluster, i.e.,
in the true distributions defined in Condition 3, Fp,c(· | ·; t = 1) = Fp,c(· | ·; t = 2) for all p, c,
and (b) a model that has the above symmetry property is used, then the limit of the MLE of
the causal effect (8) is null even if the model is incorrect. A detailed treatment of this issue
can allow for combining validity with increased efficiency in such designs as well.
5. Discussion
For the design that matches clusters of units and assigns interventions to clusters within
pairs, we proposed an approach that estimates the average causal effect while also explicitly
calibrating possibly covariate imbalance between the clusters. The approach can use only one
level of inference, or can be used in a hierarchical model.
In the Guided Care study, a first-level inference with the new approach reports estimates
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of the causal effect with smaller estimated variance than without using covariates (see Table
2). Although it is difficult to know if this is objectively true in this small sample of pairs,
the results from the permutation tests between the two approaches are also consistent with
this conclusion. A simple two-level approach, with or without covariates, makes an implicit
assumption which can invalidate causal comparison of the interventions, and explicitly address-
ing the assumption would introduce additional modeling. The covariate-calibrated approach
reports that the control condition leads to higher, albeit clinically insignificant, average overall
SF36 score compared to that under Guided Care Nurse intervention, using either a single-level
(approximate or permutation-based) analysis or a two-level permutation-based analysis.
The proposed approach is expected to be more generally robust to model misspecification
when assessing the hypothesis of no effect, if the model (10) belongs in a relatively broad
class. This expectation needs formal verification, but, if confirmed, can lead to more efficient
estimation, and, hence, more efficient use of resources.
An alternative to the proposed approach can be to break the matching and then use
regression-assisted (Donner et al., 2007) or doubly-robust estimators (Rosenblum and van der
Laan, 2010) to estimate the treatment effect. Based on Rubin’s (Rubin, 1978) theory, the
matched design is still ignorable (and so the matching can be broken) if these variables that
were used to create the matching are still available and are included in the outcomes model.
In contrast, if these variables are not used in the model, then the design is not ignorable if
the matching is broken, and this can generally lead to bias at least in the expression of the
uncertainty in inference.
6. Supplementary Materials
The R code that implements the method in this paper is available with this paper at the
Biometrics website on Wiley Online Library.
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Appendix
Proof of Result 1. We show that the MLE of δeffect based on the standard meta-analytic
likelihood (6) is generally inconsistent. To do this, consider the simple but informative case of
a population of pairs of practices as shown in Fig. 2, where µ follows the positive half of the
standard normal distribution across such pairs. Because δcrudep is µ or −µ with probabilities
(1
2
, 1
2
), marginally the normality of the distribution of δcrudep at the second level of (6) holds
with δeffect (= E(δcrudep )) = 0 and with var(δ
crude
p ) = 1. Consider also, for simplicity, that
var(δcrudep ) is known, and that within clinical practices, the number of patients sampled is a
constant n and the variances σ2p,c(t) are known and are as given in Fig. 2. Then, the maximizer
δˆeffect of the likelihood in (6) is
∑
p upδˆ
crude
p /
∑
p up where (up)
−1 = var(δcrudep ) + v
crude
p , and
vcrudep =

w1 =
2
n
, if the practice p is of typep = 1;
w2 =
1+σ2
n
, if the practice p is of typep = 2.
The probability limit of δˆeffect is E(upδˆ
crude
p )/E(up), and its sign will be the sign of E(upδˆ
crude
p ).
Here, although E(δˆcrudep ) = 0, Condition 2 fails because the sign of δ
crude
p depends on the
magnitude of the variance vp. In particular, E(upδˆ
crude
p ) = E{E(upδˆcrudep | typep)} =
µ
2
[{var(δcrudep ) + w2}−1 − {var(δcrudep ) + w1}−1] which is non zero if σ2 6= 1. This means
that even if the null hypothesis of no intervention effect on the means is correct, the standard
meta-analytic approach (6) is inappropriate if the intervention has an effect on the variance in
at least one clinical practice.
[Figure 2 here ]
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Table 1: Summary of average SF36 outcomes for uncalibrated versus calibrated approaches.
The first row block displays sample sizes; the second row block displays average outcomes that
are uncalibrated and calibrated, respectively.
pair p
1 2 3 4 5 6 7
sample size
np,c=1 17 16 42 23 52 23 28
np,c=2 38 44 43 33 42 31 43
outcome
uncalibrated
on covariates
µˆp,1(1) 36.4 36.5 39.6 39.1 39.7 33.8 39.6
µˆp,2(2) 37.3 36.6 39.3 35.3 35.2 36.4 40.9
δˆcrudep -0.8 -0.1 0.3 3.8 4.5 -2.6 -1.3(
vcrudep
)1/2
2.7 2.6 2.0 2.7 2.1 2.6 2.2
calibrated
on covariates
∗µˆcalibrp,1 37.6 38.8 39.5 38.0 38.7 35.5 40.9
∗µˆcalibrp,2 36.7 35.8 39.4 36.0 36.4 35.1 40.0
δˆcalibrp 0.9 3.0 0.1 1.9 2.3 0.5 0.8
†
(
vcalibrp
)1/2
2.1 2.4 1.5 2.0 1.7 2.2 1.7
*: calibration based on np,1 and np,2 observations in pair p
†: vcalibrp is the pth diagonal element of Σˆδˆcalibr in expression (14)
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Table 2: Results from MLE, profile MLE, Bayes estimates and permutation test in the Guided
Care program study. The covariates used for calibration are listed in the first column of Table
3; the outcome is the physical component summary of the Short Form 36 (SF36).
δˆeffect 95% C.I. s.e.(δˆeffect ) v̂ar(δ∗p)
p-value
(two-sided)
uncalibrated 1st level
on covariates MLE 0.5 (−1.4, 2.5) 1.0 − 0.59
permutation − − − − 0.61
1st+2nd level
MLE 0.6 (−1.2, 2.5) 0.9 0.7 0.50
pMLE 0.6 (−1.5, 2.7) − 0.7 −
Bayes 0.6 (−1.7, 3.0) 1.2 4.3 0.60
permutation − − − − 0.60
calibrated 1st level
on covariates MLE 1.4 (0.5, 2.2) 0.4 − <0.01
permutation − − − − 0.02
1st+2nd level
MLE 1.2 (−0.2, 2.6) 0.7 0.0 0.08
pMLE 1.2 (−0.2, 2.6) − 0.0 −
Bayes 1.3 (−0.4, 2.9) 0.9 1.5 0.13
permutation − − − − 0.02
*: represents δcrudep for the uncalibrated approach and δ
calibr
p for the calibrated approach.
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Table 3: Checking covariate imbalances within each pair. For a continuous covariate (indicated
by (a)), we calculate effect size as difference divided by pooled standard deviation. For a
categorical covariate ((indicated by (b))), odds ratio is calculated comparing rates of occurence
of each category between two clusters in a pair. To prevent infinite odds ratio, 0.5 is added to
all the cells when calculating sample odds ratios.
pair
1 2 3 4 5 6 7
age at interview(a) 0.3 -0.3 0.1 0.6 0.0 0.1 -0.1
Chronic Illness Burden(a) 0.5 -0.6 0.0 0.0 -1.1 0.1 0.6
SF36 Mental(a) -0.3 0.1 0.3 0.2 0.3 -0.6 -0.5
SF36 Physical(a) -0.1 -0.4 0.1 0.5 0.4 -0.6 -0.3
lives alone(b) 1.4 0.8 0.7 0.7 1.6 0.9 0.5
>high school education(b) 0.4 0.5 0.7 1.4 0.8 0.8 1.1
Female(b) 2.4 0.6 1.0 0.6 1.0 2.5 1.1
race(b)
Caucasian 0.5 0.2 0.9 0.8 1.5 0.5 0.7
African American 2.2 0.9 1.2 1.2 0.8 1.6 1.2
other 2.2 15.0 1.0 1.4 0.6 1.3 1.5
finances at end of month(b)
some money left over 0.0 0.7 1.4 0.7 1.5 0.7 0.6
just enough to make ends meet 8.9 1.0 0.3 1.3 0.6 1.2 1.4
not enough to make ends meet 18.2 8.4 7.0 1.0 1.2 2.0 1.6
self rated health(b)
≥very good 0.3 0.3 0.8 2.2 0.3 0.8 0.6
good 2.6 3.4 1.4 0.4 2.5 0.8 1.4
fair 0.9 0.9 0.4 0.3 2.5 4.2 0.5
poor 6.8 1.5 3.1 4.4 2.0 4.2 2.1
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Clinical practice "1"
(actually assigned 
control)
Clinical practice "2"
(actually assigned 
intervention)
(mean, variance)
(if assigned control)
(mean, variance)
(if assigned intervention)
Pair p
(mean, variance)
(if assigned control)
(mean, variance)
(if assigned intervention)
Pair p'
(µp,1 (1) , σ
2
p,1 (1))
(µp,1 (2) , σ
2
p,1 (2))
(µp,2 (1) , σ
2
p,2 (1))
(µp,2 (2) , σ
2
p,2 (2))
(µp ,1 (1) , σ
2
p ,1 (1))
(µp ,1 (2) , σ
2
p ,1 (2))
(µp ,2 (1) , σ
2
p ,2 (1))
(µp ,2 (2) , σ
2
p ,2 (2))
equal
equal
Figure 1: The underlying structure of the paired-cluster randomized design. The top part
(observed pair p) and bottom part (observed pair p′) are the two possible ways in which a single
pair can be manifested in the design. Observed pair p has two clinical practices (represented
by the two squares). For each clinical practice, the first row shows the mean and variance of
patient outcomes if the clinical practice is assigned control and the second row shows the mean
and variance if assigned intervention. The clinical practice actually assigned control is indicated
by its placement in column “1” , and the clinical practice actually assigned intervention is in
column “2”. The solid (nonsolid) ellipsoids show the means and variances that can (cannot)
be estimated directly. Observed pair p′ shows how the same pair would be manifested in the
design if the assignment of treatment to clinical practices were in reverse (a line with arrows
connects the same clinical practice in these two different assignments). Condition 1 means that
each of the two manifestations, p and p′ has the same probability.
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Clinical practice "1"
(actually assigned 
control)
Clinical practice "2"
(actually assigned 
intervention)
(mean, variance)
(if assigned control)
(mean, variance)
(if assigned intervention)
Pair p (type=1)
(mean, variance)
(if assigned control)
(mean, variance)
(if assigned intervention)
Pair p' (type=2)
(0 , 1)
(0 , σ2 )
(µ, 1)
(µ, 1)
(µ, 1)
(µ, 1)
(0 , 1)
(0 , σ2 )
equal
equal
Figure 2: Structure for the example used in the proof of Result 1 (Appendix 1). Shown is
one true type of pair and the two types of observed pairs to which it can give rise, depending
on which clinical practice is assigned control. In each parentheses shown are the mean and
variance of the potential outcomes of patients of the corresponding clinical practice and under
a give treatment, as denoted in Fig. 1.
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Figure 3: Checking second level dependence. Left: estimates of
√
vcrudep versus δ
crude
p ; Right:
estimates of
√
vcalibrp versus δ
calibr
p , where v
calibr
p are the diagonal elements of Σδˆcalibr .
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